Overview

An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia

Status:
Terminated
Trial end date:
2018-12-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether treatment with atabecestat slows cognitive decline compared with placebo treatment, as measured by a composite cognitive measure, the Preclinical Alzheimer Cognitive Composite (PACC), in amyloid-positive participants who are asymptomatic at risk for developing Alzheimer's dementia.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Janssen Research & Development, LLC